Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ASX:MVP'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 81 Med: 467.16 Max: 1394.78
Current: 98
During the past 13 years, the highest PE Ratio (TTM) of Medical Developments International was 1394.78. The lowest was 81.00. And the median was 467.16.
ASX:MVP's PE Ratio (TTM) is ranked worse than 91.79% of 633
companies
in the Drug Manufacturers industry
Industry Median: 22.15
vs ASX:MVP: 98.00
During the past 13 years, Medical Developments International's highest 3-Year average EPS without NRI Growth Rate was 71.00% per year. The lowest was -67.40% per year. And the median was -7.20% per year.
Medical Developments International (ASX:MVP) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Medical Developments International PE Ratio (TTM) Related Terms
Medical Developments International PE Ratio (TTM) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Developments International PE Ratio (TTM) Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Medical Developments International's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medical Developments International PE Ratio (TTM) vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medical Developments International's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Medical Developments International's PE Ratio (TTM) falls into.
Medical Developments International PE Ratio (TTM) Calculation
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Medical Developments International's Share Price of today is A$0.49.
For company reported semi-annually, Medical Developments International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Medical Developments International (ASX:MVP) has a PE Ratio (TTM) of 98.00 as of Aug. 26, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Medical Developments International and its competitors. This is 79% below median its historical median of 467.16. Over the past decade, Medical Developments International's PE Ratio (TTM) has ranged from 81.00 to 1,394.78. According to the industry distribution chart, Medical Developments International ranks #581 out of 633 companies in the Drug Manufacturers industry, placing it in the top 91.8%.
Is Medical Developments International's PE Ratio (TTM) too high?
Medical Developments International's current PE Ratio (TTM) of 98.00 is 79% below median its 10-year median of 467.16. Over the past 10 years, this metric has ranged from a low of 81.00 to a high of 1,394.78. The Drug Manufacturers industry median PE Ratio (TTM) is 22.15. Medical Developments International's value of 98.00 is 342.4% above this industry median. Based on the distribution chart, Medical Developments International ranks #581 out of 633 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medical Developments International has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medical Developments International's PE Ratio (TTM) compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medical Developments International ranks #581 out of 633 companies for PE Ratio (TTM). This places Medical Developments International in the lower half of its industry. The industry median PE Ratio (TTM) is 22.15. Medical Developments International's value of 98.00 is 342.4% above this benchmark. Historically, Medical Developments International's own PE Ratio (TTM) has ranged from 81.00 to 1,394.78 over the past decade. While the company's 10-year median is 467.16 vs. the industry median of 22.15, Medical Developments International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Drug Manufacturers company?
The median PE Ratio (TTM) among Drug Manufacturers companies is 22.15, based on 633 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medical Developments International's current PE Ratio (TTM) of 98.00 is 342.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Medical Developments International and its competitors. For the Drug Manufacturers industry, the median PE Ratio (TTM) is 22.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medical Developments International's current PE Ratio (TTM) is 98.00, which is 79% below median its own 10-year median of 467.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Developments International stock overvalued right now?
Based on GuruFocus' analysis, Medical Developments International (ASX:MVP) is currently considered Fairly Valued. The stock's GF Value™ is A$0.52, compared to a current price of A$0.49 — trading 5.8% below its estimated fair value. The current PE Ratio (TTM) is 98.00, which is 79% below median its 10-year median of 467.16 and 342.4% above the Drug Manufacturers industry median of 22.15. Medical Developments International's overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Medical Developments International (ASX:MVP), the current PE Ratio (TTM) is 98.00 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medical Developments International (ASX:MVP) Overvalued in 2026?
Based on GuruFocus' analysis, Medical Developments International stock appears to be undervalued.
The current stock price of A$0.49 is trading 5.8% below its estimated GF Value™ of A$0.52.
GuruFocus considers Medical Developments International to be Fairly Valued.
Key valuation signals for ASX:MVP:
PE Ratio (TTM): 98.00 (79% below median its 10-year median of 467.16)
GF Value™: A$0.52 vs. price of A$0.49 (5.8% below fair value)
Industry Position: 342.4% above the Drug Manufacturers median (#581 of 633)
No single metric tells the full story. See the ASX:MVP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medical Developments International Ltd is a specialized healthcare company. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The segments of the company are Pain Management and Respiratory. The company derives maximum revenue from the Pain management segment.
54GF Score
Get the complete analysis for ASX:MVP
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MVP has been successfully added to your 
